New combo therapy aims to shrink Hard-to-Treat tumors
NCT ID NCT07272590
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug combination (QLC5513 plus QL1706, with or without platinum chemo) in people with advanced solid tumors that have spread. The goal is to see if the treatment can shrink tumors and to check its safety. About 290 participants will take part, and the study is for those who cannot have surgery or radiation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can your own immune cells fight advanced cancer?
- Can a radioactive antibody light up hidden cancers on PET scans?
- Blood test may let cancer patients take safe breaks from immunotherapy
- Off-the-Shelf cell therapy takes on Hard-to-Treat cancers
- New drug duo aims to reboot immune attack on Hard-to-Treat cancers